Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
9.74
+0.19 (1.99%)
At close: Jun 27, 2025, 4:00 PM
9.51
-0.23 (-2.36%)
After-hours: Jun 27, 2025, 7:14 PM EDT
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $28.52M in the quarter ending March 31, 2025, with 1,391.58% growth. This brings the company's revenue in the last twelve months to $81.86M, up 3,055.71% year-over-year. In the year 2024, Phathom Pharmaceuticals had annual revenue of $55.25M with 8,001.47% growth.
Revenue (ttm)
$81.86M
Revenue Growth
+3,055.71%
P/S Ratio
7.92
Revenue / Employee
$191,707
Employees
427
Market Cap
678.37M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PHAT News
- 3 days ago - Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha
- 5 days ago - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 12 days ago - Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032 - GlobeNewsWire
- 18 days ago - Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy - Seeking Alpha
- 22 days ago - Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 - GlobeNewsWire
- 6 weeks ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript - Seeking Alpha